New latency-promoting agents for a block-and-lock functional cure strategy.
| Autor: | Pellaers E; Molecular Virology and Gene Therapy, KU Leuven, Leuven, Flanders, Belgium., Denis A, Debyser Z |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Current opinion in HIV and AIDS [Curr Opin HIV AIDS] 2024 May 01; Vol. 19 (3), pp. 95-101. Date of Electronic Publication: 2024 Feb 27. |
| DOI: | 10.1097/COH.0000000000000844 |
| Abstrakt: | Purpose of Review: Currently, HIV-infected patients are treated with antiretroviral therapy. However, when the treatment is interrupted, viral rebound occurs from latently infected cells. Therefore, scientists aim to develop an HIV-1 cure which eradicates or permanently silences the latent reservoir. Recent Findings: Previously, scientists focused on the shock-and-kill cure strategy, which aims to eradicate the latent reservoir using latency-reactivating agents. Limited success shifts the interest towards the block-and-lock cure approach, which aims to achieve a functional cure by "blocking" HIV-1 transcription and "locking" the provirus in a deep latent state, resistant to treatment-interruption. In this strategy, latency promoting agents are used to induce transcriptional silencing and alter the epigenetics environment at the HIV promotor. Summary: For the block-and-lock cure strategy to succeed more investigation into the transcriptional and epigenetic regulation of HIV-1 gene expression is necessary to design optimal latency-promoting agents. In this review, we will discuss the latency promoting agents that have been described in literature during the past 2 years (2022-2023). (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|